Goldline Pharmaceutical IPO Opens Today 12 May 2026: GMP at Rs 16-17 Signals 37-40% Listing Gain, Price Band Rs 41-43

The Goldline Pharmaceutical IPO opens for subscription today, 12 May 2026, on the BSE SME platform with a price band of Rs 41 to Rs 43 per share for a Rs 11.61 crore SME fresh issue. The Goldline Pharmaceutical IPO is generating one of the highest grey market premiums of any SME IPO currently open, with GMP at Rs 16 to Rs 17 as of 11 May 2026, signalling an expected listing gain of approximately 37 to 40 percent over the upper band of Rs 43. The implied listing price based on current GMP stands at approximately Rs 59 to Rs 60.

Goldline Pharmaceutical Ltd is a Nagpur-based pharmaceutical marketing company founded in 2005 that operates on an asset-light, third-party contract manufacturing model. With 15 contract manufacturers and 8 distributors, the company markets pharmaceutical products across five branded segments under the Goldline brand in Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan and Bihar.

Goldline Pharmaceutical IPO Key Details

• Exchange: BSE SME
• Issue Opens: 12 May 2026 (today)
• Issue Closes: 14 May 2026
• Allotment Date: 15 May 2026
• Refund and Credit of Shares: 18 May 2026
• Listing Date: 19 May 2026
• Price Band: Rs 41 to Rs 43 per share
• Face Value: Rs 10 per share
• Issue Size: Rs 11.61 crore (100% fresh issue, 27,00,000 shares)
• Lot Size: 3,000 shares
• Minimum Retail Application: 2 lots (6,000 shares) at Rs 2,58,000 at upper band
• Minimum HNI Application: 3 lots (9,000 shares) at Rs 3,87,000
• Category Split: QIB 50%, Retail 35%, NII 15%
• GMP (as of 11 May 2026): Rs 16 to Rs 17 (37 to 40% premium over upper band)
• Implied Listing Price (GMP basis): Approximately Rs 59 to Rs 60
• P/E at Issue Price: 10.48 times (at Rs 43 upper band, fair versus industry P/E)
• Lead Manager: Cumulative Capital Pvt Ltd
• Registrar: Bigshare Services Pvt Ltd
• Market Maker: Nirman Share Brokers

Track Goldline Pharmaceutical IPO Day 1 subscription status live on the Check the Univest Screener for live data.

About Goldline Pharmaceutical: Business Model and Portfolio

Asset-Light Pharma Marketing Company With 20 Years of Operations

Goldline Pharmaceutical Limited was founded on 28 February 2005 by Amol Mujumdar in Nagpur, Maharashtra. The company is an asset-light pharmaceutical marketing and distribution business that does not own or operate any manufacturing facility. All products are manufactured by 15 third-party contract manufacturers to Goldline’s specifications, allowing the company to focus its capital on branding, sales force expansion and distribution rather than plant and equipment.

The company distributes through 8 distributors, with 60-day credit terms extended to distributors. Geographic concentration is a notable risk factor: Maharashtra and Madhya Pradesh together account for over 70 percent of revenue. The company also sells in Odisha, Jharkhand, Tamil Nadu, Rajasthan and Bihar through its expanding multi-state distribution network.

Five Product Segments Under the Goldline Brand

• Goldline Pharma: 42 products across physicians, orthopedics, ENT, chest physicians, surgery, gastroenterology, neurology and urology.
• Goldline Cardinal: 54 products for diabetologists, endocrinologists, cardiologists and general physicians.
• Goldline Aayushman: 18 products for pediatricians, neonatologists and general practitioners.
• Goldline InLife: 22 products for intensivists, critical care consultants, super-specialty surgeons and physicians.
• Goldline Wellness: 10 products for supportive care in cancer therapy.

Financials: Revenue Growth and Improving ROE

Goldline Pharmaceutical reported FY25 revenue of Rs 28.06 crore, up 19 percent from Rs 23.57 crore in FY24. PAT grew to Rs 2.83 crore in FY25 from Rs 1.81 crore in FY24, a 56.4 percent year-on-year jump. ROE improved to 27.34 percent in FY25 and debt-to-equity declined to 1.54 times. The P/E at the Rs 43 upper band is 10.48 times, which multiple sources flag as fair to attractive relative to the pharmaceutical marketing sector P/E.

Tap to Access Best Research Pieces on Univest

Goldline Pharmaceutical IPO GMP Day 1: What the Rs 16-17 Signals

The Goldline Pharmaceutical IPO GMP of Rs 16 to Rs 17 as of 11 May 2026 is stable and consistent with the most optimistic pre-subscription GMP readings, which ranged from Rs 8 to Rs 17 across different grey market sources. The Rs 17 high on listing eve, implying a Rs 60 expected listing price versus the Rs 43 upper band, represents one of the highest GMP-to-issue-price ratios among all current SME IPOs.

For Day 1 of subscription on 12 May 2026, expect slow subscription build-up in the morning as QIBs (who get 50% allocation) and HNI applicants typically wait for Day 2 and Day 3 before placing bids. Day 1 undersubscription in the GMP-backed categories is normal and should not be interpreted as a negative signal for the Goldline Pharmaceutical IPO.

Key Risks in the Goldline Pharmaceutical IPO

• Related Party Revenue Concentration: 22.04% of company revenue comes from three promoter-group entities (Numerius Healthcare, Nucleage Lifescience, Nucleage Pharma Solutions) acting as distributors. This creates a potential conflict of interest and revenue sustainability risk.
• Geographic Concentration: Maharashtra alone contributes approximately 44% of revenue. Dependence on a single state makes revenue vulnerable to local market conditions.
• Third-Party Manufacturing Risk: No manufacturing facility of its own. Quality failure, regulatory action or capacity shortfall at any of the 15 contract manufacturers could disrupt the business.
• Small Scale: Rs 28.06 crore revenue and Rs 2.83 crore PAT represent a very early-stage business. Any working capital or cash flow stress could disproportionately impact operations.
• Ongoing Litigations: Tax litigations of Rs 271.23 lakh in direct tax and Rs 63.70 lakh in indirect tax are outstanding. These represent financial contingencies investors should be aware of.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces on Goldline Pharmaceutical IPO subscription status and all active SME IPO GMP tracking!

Conclusion

The Goldline Pharmaceutical IPO opens today on 12 May 2026 with the highest GMP among all currently open SME IPOs at Rs 16 to Rs 17, implying a listing gain of 37 to 40 percent over the Rs 43 upper band. The Nagpur pharma marketing company’s asset-light model, improving ROE and fair PE valuation of 10.48 times are positives. Related party revenue, geographic concentration in Maharashtra and third-party manufacturing dependency are the key risks to evaluate before applying. Track live Day 1 subscription data on Univest and consult a SEBI-registered advisor before making any investment decision.

FAQs on Goldline Pharmaceutical IPO

What is the Goldline Pharmaceutical IPO price band and issue size?

Ans. The Goldline Pharmaceutical IPO price band is Rs 41 to Rs 43 per share for a total issue size of Rs 11.61 crore. The issue is entirely a fresh issue with no OFS component, meaning all proceeds go directly to the company for working capital and debt repayment.

What is the Goldline Pharmaceutical IPO GMP on Day 1?

Ans. The Goldline Pharmaceutical IPO GMP stands at Rs 16 to Rs 17 as of 11 May 2026 (the day before the issue opened), implying an expected listing price of approximately Rs 59 to Rs 60 against the upper band of Rs 43. This is approximately a 37 to 40 percent listing premium. GMP is unofficial and can change before the 19 May listing date.

What does Goldline Pharmaceutical do?

Ans. Goldline Pharmaceutical Ltd is a Nagpur-based pharmaceutical marketing company incorporated in 2005. It markets pharmaceutical products under 5 sub-brands across orthopedics, cardiology, diabetology, pediatrics, critical care and wellness segments. All manufacturing is outsourced to 15 third-party contract manufacturers while the company focuses on branding and distribution across 7 Indian states.

Should I apply for the Goldline Pharmaceutical IPO?

Ans. The Goldline Pharmaceutical IPO GMP and fair PE valuation are positives. However, the related-party revenue concentration of 22%, geographic concentration in Maharashtra, third-party manufacturing risk and small revenue base of Rs 28 crore make this suitable only for moderate-risk investors with tolerance for SME illiquidity. Consult a SEBI-registered advisor before applying.

When is the Goldline Pharmaceutical IPO allotment and listing?

Ans. The Goldline Pharmaceutical IPO allotment date is 15 May 2026. Shares are credited on 18 May 2026 and listing is expected on BSE SME on 19 May 2026. Allotment status can be checked on the Bigshare Services registrar website from 15 May.

Recent Article

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026

Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026

Why Is PSP Projects Share Price Falling Key Reasons 2026